Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edivoxetine in Pediatric ADHD
NCT00965419Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2009
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label trial of edivoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants With At Least One Serious Adverse Event at 252 weeks and Number of Participants With At Least One Serious Adverse Event at 252 weeks. Started Sep 2009; status: terminated.
02
Drugs
edivoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00965419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00965419.